Edition:
United States

Pain Therapeutics Inc (PTIE.OQ)

PTIE.OQ on NASDAQ Stock Exchange Capital Market

0.86USD
4:00pm EDT
Change (% chg)

$-0.04 (-4.88%)
Prev Close
$0.90
Open
$0.92
Day's High
$0.92
Day's Low
$0.81
Volume
208,466
Avg. Vol
98,975
52-wk High
$12.80
52-wk Low
$0.81

Select another date:

Mon, Aug 6 2018

FDA declines to approve Pain Therapeutics' opioid drug, shares plunge

The U.S. Food and Drug Administration declined to approve Pain Therapeutics Inc's abuse-deterrent opioid treatment Remoxy for the fourth time, sending the company's shares down 35 percent to a record low.

UPDATE 2-FDA declines to approve Pain Therapeutics' opioid drug, shares plunge

* Shares fall 35 pct to record low (Adds analyst comment, updates share movement)

U.S. FDA declines to approve Pain Therapeutics' opioid drug

Aug 6 Pain Therapeutics' said on Monday that the U.S. Food and Drug Administration declined to approve the company's opioid drug for the management of severe pain as the benefits of the drug did not outweigh the risk.

BRIEF-Pain Therapeutics Q1 Loss Per Share $0.33

* PAIN THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE ON REMOXY® ER

BRIEF-Pain Therapeutics Announces FDA Advisory Committee Meeting For Remoxy ER

* PAIN THERAPEUTICS ANNOUNCES FDA ADVISORY COMMITTEE MEETING FOR REMOXY ER®

BRIEF-FDA Accepts Remoxy NDA For Review, Sets PDUFA Date Of Aug 7, 2018

* FDA ACCEPTS REMOXY® NDA FOR REVIEW, SETS PDUFA DATE OF AUGUST 7, 2018

Select another date: